A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
A phase 3 trial of Trastuzumab rezetecan, Pertuzumab, Docetaxel and Trastuzumab in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06057610 by Jiangsu HengRui Medicine Co., Ltd., with 868 participants enrolled, started 2023-11-01 and due to reach its primary completion in 2026-07-15. Interventions recorded: SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection and Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection.
Similar pages
not linked directly; found by shared links- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Trastuzumab rezetecan, Pertuzumab, Trastuzumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, HER2-positive breast cancer and the tag pipeline.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Trastuzumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Shares Trastuzumab rezetecan, Pertuzumab, Docetaxel, Trastuzumab.
- TrialSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Shares Trastuzumab rezetecan, Docetaxel, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Shares Trastuzumab rezetecan, Trastuzumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.